Organogenesis (NASDAQ:ORGO) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Organogenesis (NASDAQ:ORGO) has received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook from the research firm.
• Despite the "sell" rating, analysts from Cantor Fitzgerald have increased their price target for Organogenesis from $7.00 to $9.00, suggesting potential for positive stock performance.
• The company reported a quarterly loss with an EPS of ($0.09), missing expectations, and has a market cap of approximately $523.93 million.

Organogenesis (NASDAQ:ORGO - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities analysts have also weighed in on ORGO. Cantor Fitzgerald increased their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, August 8th. BTIG Research reiterated a "buy" rating and issued a $7.00 target price on shares of Organogenesis in a report on Friday, September 26th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Organogenesis presently has an average rating of "Hold" and a consensus target price of $7.33.

Organogenesis Stock Down 0.2%

NASDAQ:ORGO opened at $4.13 on Wednesday. The firm has a market cap of $523.93 million, a PE ratio of -29.50 and a beta of 1.68. Organogenesis has a 12 month low of $2.61 and a 12 month high of $6.71. The company's 50-day moving average price is $4.67 and its two-hundred day moving average price is $4.21.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The firm had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. On average, research analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC bought a new position in shares of Organogenesis in the 2nd quarter valued at about $24,804,000. Assenagon Asset Management S.A. grew its position in shares of Organogenesis by 69.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company's stock valued at $20,488,000 after acquiring an additional 1,997,038 shares during the period. Vanguard Group Inc. grew its position in shares of Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after acquiring an additional 841,618 shares during the period. Acadian Asset Management LLC grew its position in shares of Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company's stock valued at $8,862,000 after acquiring an additional 91,118 shares during the period. Finally, Driehaus Capital Management LLC bought a new position in shares of Organogenesis in the 1st quarter valued at about $7,756,000. Institutional investors own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.